{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:17:09Z","timestamp":1770823029495,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":234,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathology International"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>T\u2010cell lymphomas are a biologically heterogeneous group of diseases with varying clinical presentations and outcomes. We tried to understand the effect of Epstein\u2013Barr virus (EBV) on lymphogenesis, prognostic factors and drug resistance of T\u2010cell lymphomas, and to establish their relationship with international prognostic factors. Formalin\u2010fixed paraffin\u2010embedded tissue sections from 35 patients (12 women and 23 men) with T\u2010cell lymphomas were examined to detect the presence of EBV using RNA <jats:italic>in situ<\/jats:italic> hybridization for EBV\u2010encoded small nuclear RNA (EBER) 1\/2 and immunohistochemical stain for latent membrane protein (LMP)\u20101. We also tried to establish the expression of p53 and P\u2010glycoprotein (P\u2010gp) using immunohistochemistry. The distribution according to the subgroup was: two T\u2010lymphoblastic lymphomas, 13 NK\/T\u2010cell lymphomas, one angioimmunoblastic T\u2010cell lymphoma, 17 peripheral T\u2010cell lymphomas, unspecified, and two anaplastic large cell lymphomas. The EBER was detected in 15 of 35 T\u2010cell lymphomas (42.9%) and among these it was detected in five of 17 nodal lymphomas (29.4%) and 10 of 18 extranodal lymphomas (55.6%). There was close correlation between EBER positivity and NK\/T\u2010cell lymphoma (<jats:italic>P<\/jats:italic><jats:bold>=<\/jats:bold> 0.032). Expression of LMP was found in a proportion of tumor cells in seven of the 15 EBER\u2010positive cases (46.7%). There was no correlation between EBER expression and complete response (CR rate), but coexpression of EBER and p53 was associated with treatment failure (<jats:italic>P<\/jats:italic><jats:bold>=<\/jats:bold> 0.047). The 18 patients (51.4%) with p53 expression had significantly poorer outcomes compared with the 17 patients without p53 expression (CR rate, <jats:italic>P<\/jats:italic><jats:bold>&lt;<\/jats:bold> 0.0005; overall survival, <jats:italic>P<\/jats:italic><jats:bold>=<\/jats:bold> 0.0102). Twenty of 35 patients (57.1%) were positive for P\u2010gp expression. P\u2010gp expression was significantly associated with treatment failure (<jats:italic>P<\/jats:italic><jats:bold>=<\/jats:bold> 0.001) and overall survival (<jats:italic>P<\/jats:italic><jats:bold>=<\/jats:bold> 0.0089). Seventeen of 35 patients (48.6%) treated with systemic chemotherapy or radiation therapy achieved a CR after initial treatment. When the prognostic factors were grouped using the international prognostic index, the CR rate was 58.8% for the low risk group, 50.0% for the low\u2013intermediate risk group, 14.3% for the high\u2013intermediate risk group, and 0% for the high risk group. In conclusion, high incidence of EBV was detected among Korean patients with T\u2010cell lymphomas. Our study supports the prediction that patients who express p53 and P\u2010gp have a poorer prognosis than those who do not and this should be considered when treatment strategies for individual patients are selected.<\/jats:p>","DOI":"10.1046\/j.1440-1827.2001.01214.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T17:16:46Z","timestamp":1047489406000},"page":"355-363","source":"Crossref","is-referenced-by-count":24,"title":["Epstein\u2013Barr virus infection, drug resistance and prognosis in Korean T\u2010 and NK\u2010cell lymphomas"],"prefix":"10.1111","volume":"51","author":[{"given":"Chan Kwon","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungja","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang In","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Kee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19980815)83:4<806::aid-cncr26>3.3.co;2-8"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008418727472"},{"issue":"1","key":"e_1_2_5_4_2","first-page":"S46","article-title":"Extranodal peripheral T\u2010cell and NK\u2010cell neoplasms","volume":"111","author":"Jaffe ES","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/fgbi.1996.0018"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/mr.59.3.387-405.1995","article-title":"Immune regulation in Epstein\u2010Barr virus\u2010associated diseases.","volume":"59","author":"Khanna R","year":"1995","journal-title":"J. Microbiol. Rev"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91524-7"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.59.1.94"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90002-M"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711750303"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V85.2.552.552","article-title":"Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.","volume":"85","author":"Knowles DM","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91837-K"},{"key":"e_1_2_5_14_2","first-page":"86","article-title":"Epstein\u2010Barr viral DNA in tissues of Hodgkin\u2019s disease.","volume":"129","author":"Weiss LM","year":"1987","journal-title":"Am. J. Pathol."},{"key":"e_1_2_5_15_2","first-page":"1315","article-title":"A survey of Epstein\u2010Barr virus gene expression in sporadic non\u2010Hodgkin\u2019s lymphomas. Detection of Epstein\u2010Barr virus in a subset of peripheral T\u2010cell lymphomas.","volume":"140","author":"Hamilton\u2010Dutoit SJ","year":"1992","journal-title":"Am. J. Pathol."},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood.V88.10.4012.bloodjournal88104012","article-title":"p21\/WAF1 cyclin\u2010kinase inhibitor expression in non\u2010Hodgkin\u2019s lymphomas: a potential marker of p53 tumor\u2010suppressor gene function.","volume":"88","author":"Chilosi M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370804"},{"key":"e_1_2_5_18_2","first-page":"1085","article-title":"Disrupted p53 function as predictor of treatment failure and poor prognosis in B\u2010 and T\u2010cell non\u2010Hodgkin\u2019s lymphoma.","volume":"5","author":"Moller MB","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90147-8"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2000.15.1.59"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood.V81.9.2215.2215","article-title":"Clinical significance of P\u2010glycoprotein in multidrug resistance malignancies.","volume":"81","author":"Arceci RJ.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2453"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460","article-title":"International Prognostic Index for aggressive non\u2010Hodgkin\u2019s lymphoma is valid for all malignancy grades.","volume":"86","author":"Hermans J","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2296"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1343"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1994.tb01289.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8652(199903)60:3<205::aid-ajh7>3.3.co;2-a"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V77.4.799.799","article-title":"Aggressive peripheral T\u2010cell lymphomas containing Epstein\u2010Barr viral DNA: a clinicopathologic and molecular analysis.","volume":"77","author":"Su IJ","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910510410"},{"issue":"1","key":"e_1_2_5_31_2","first-page":"S8","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report.","volume":"111","author":"Jaffe ES","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019606-199203000-00037"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428199909169621"},{"key":"e_1_2_5_34_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000150435","article-title":"Pathogenic role of Epstein\u2010Barr virus in human cancer.","volume":"38","author":"Takada K","year":"1995","journal-title":"Intervirology"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(86)90803-2"},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1128\/jvi.64.5.2309-2318.1990","article-title":"Epstein\u2010Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA\u20102 and LMP1 cooperatively induce CD23.","volume":"64","author":"Wang F","year":"1990","journal-title":"J. Virol."},{"key":"e_1_2_5_37_2","first-page":"523","article-title":"Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein\u2010Barr virus are frequent in lymphoproliferative disorders.","volume":"10","author":"Knecht H","year":"1995","journal-title":"Oncogene"},{"key":"e_1_2_5_38_2","first-page":"793","article-title":"Clonal versus polyclonal Epstein\u2010Barr virus infection in nasopharyngeal carcinoma cell lines.","volume":"76","author":"Lin CT","year":"1997","journal-title":"Lab. Invest."},{"key":"e_1_2_5_39_2","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1128\/jvi.70.7.4849-4853.1996","article-title":"Epstein\u2010Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF\u2010kappa B activity.","volume":"70","author":"Chen W","year":"1996","journal-title":"J. Virol."},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5455"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07124.x"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00843.x"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/316817a0"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008332318884"},{"key":"e_1_2_5_45_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V93.2.599","article-title":"P\u2010glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P\u2010glycoprotein function by cyclosporin A and its analogue, PSC833.","volume":"93","author":"Egashira M","year":"1999","journal-title":"Blood"}],"container-title":["Pathology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1827.2001.01214.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1827.2001.01214.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:48:05Z","timestamp":1697507285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1827.2001.01214.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1440-1827.2001.01214.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1827.2001.01214.x","archive":["Portico"],"relation":{},"ISSN":["1320-5463","1440-1827"],"issn-type":[{"value":"1320-5463","type":"print"},{"value":"1440-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}